Canaccord Genuity Starts Zynerba Pharmaceuticals (ZYNE) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Canaccord Genuity Reiterates Buy on Zynerba Pharma (ZYNE) Following GW Pharmaceutical's (GWPH) Positive CBD Data
September 16, 2015 8:45 AM EDTCanaccord Genuity maintained a Buy rating and $35.00 price target on Zynerba Pharmaceuticals (NASDAQ: ZYNE) following GW Pharmaceuticals (NASDAQ: GWPH) positive data from its proof-of-concept trial assessing the efficacy of its liquid cannabidiol (CBD). The treatment arm consistently beat... More
